MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 56 filers reported holding MEREO BIOPHARMA GROUP PLC in Q2 2023. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $270,000 | -97.8% | 75,000 | -97.9% | 0.01% | -97.8% |
Q1 2024 | $12,056,530 | -29.2% | 3,653,494 | -50.4% | 0.45% | -41.8% |
Q4 2023 | $17,026,636 | +79.2% | 7,370,838 | +0.1% | 0.77% | +50.1% |
Q3 2023 | $9,500,125 | -2.3% | 7,364,438 | 0.0% | 0.51% | -1.3% |
Q2 2023 | $9,721,058 | +86.7% | 7,364,438 | 0.0% | 0.52% | +136.4% |
Q1 2023 | $5,205,921 | -5.7% | 7,364,438 | 0.0% | 0.22% | -5.2% |
Q4 2022 | $5,523,329 | -12.9% | 7,364,438 | 0.0% | 0.23% | -11.8% |
Q3 2022 | $6,342,000 | -38.1% | 7,364,438 | -19.4% | 0.26% | -32.4% |
Q2 2022 | $10,239,000 | 0.0% | 9,142,067 | 0.0% | 0.39% | +24.3% |
Q1 2022 | $10,239,000 | -30.0% | 9,142,067 | 0.0% | 0.31% | +10.6% |
Q4 2021 | $14,627,000 | -33.9% | 9,142,067 | 0.0% | 0.28% | -24.1% |
Q3 2021 | $22,124,000 | -19.3% | 9,142,067 | +5.7% | 0.37% | -9.0% |
Q2 2021 | $27,418,000 | +27.8% | 8,649,300 | +35.9% | 0.41% | +29.3% |
Q1 2021 | $21,452,000 | +118.0% | 6,365,500 | +131.6% | 0.32% | +124.8% |
Q4 2020 | $9,841,000 | – | 2,748,999 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tejara Capital Ltd | 2,435,806 | $1,721,871 | 0.88% |
Monaco Asset Management SAM | 1,316,245 | $930,454 | 0.28% |
DAFNA Capital Management LLC | 1,096,513 | $775,125 | 0.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 7,364,438 | $5,205,921 | 0.22% |
Clearline Capital LP | 2,052,709 | $1,451,060 | 0.22% |
Rubric Capital Management LP | 10,366,120 | $7,327,810 | 0.19% |
Orbimed Advisors | 7,747,891 | $5,476,984 | 0.11% |
Rock Springs Capital Management LP | 6,244,897 | $4,414,518 | 0.10% |
683 Capital Management, LLC | 2,000,000 | $1,413,801 | 0.10% |
Privium Fund Management (UK) Ltd | 177,200 | $131,128 | 0.10% |